Immunogenotype of B-PLL patients
| Patient . | t(11;14) . | IGH rearrangement* . | Percentage identity in IGHV . | ||
|---|---|---|---|---|---|
| IGHV . | IGHD . | IGHJ . | |||
| B-PLL1 | No | 3-9 | 3-16 | 4*02 | 92.2 |
| B-PLL2 | No | 3-53 | ND | 4*02 | 89.8 |
| B-PLL3 | No | 4-39 | 5-5 | 5*02 | 98.7 |
| B-PLL4 | No | 3-49 | 3-10 | 5*02 | 99.6 |
| B-PLL5 | No | 3-43 | 6-19 | 4*02 | 93.8 |
| B-PLL6 | No | 3-33 | ND | 6*02 | 93.8 |
| B-PLL7 | Yes | 3-23 | 6-6 | 4*02 | 100 |
| B-PLL8 | Yes | 6-1 | 4-17 | 4*02 | 96.5 |
| B-PLL9 | Yes | 4-61 | 4-17 | 4*02 | 95.7 |
| B-PLL10 | Yes | 4-59 | 1-20 | 3*02 | 90.5 |
| B-PLL11 | Yes | 3-23 | 4-11 | 4*02 | 100 |
| B-PLL12 | Yes | 1-8 | 1-1 | 5*02 | 100 |
| B-PLL13 | Yes | 3-23 | 3-9 | 4*02 | 100 |
| Patient . | t(11;14) . | IGH rearrangement* . | Percentage identity in IGHV . | ||
|---|---|---|---|---|---|
| IGHV . | IGHD . | IGHJ . | |||
| B-PLL1 | No | 3-9 | 3-16 | 4*02 | 92.2 |
| B-PLL2 | No | 3-53 | ND | 4*02 | 89.8 |
| B-PLL3 | No | 4-39 | 5-5 | 5*02 | 98.7 |
| B-PLL4 | No | 3-49 | 3-10 | 5*02 | 99.6 |
| B-PLL5 | No | 3-43 | 6-19 | 4*02 | 93.8 |
| B-PLL6 | No | 3-33 | ND | 6*02 | 93.8 |
| B-PLL7 | Yes | 3-23 | 6-6 | 4*02 | 100 |
| B-PLL8 | Yes | 6-1 | 4-17 | 4*02 | 96.5 |
| B-PLL9 | Yes | 4-61 | 4-17 | 4*02 | 95.7 |
| B-PLL10 | Yes | 4-59 | 1-20 | 3*02 | 90.5 |
| B-PLL11 | Yes | 3-23 | 4-11 | 4*02 | 100 |
| B-PLL12 | Yes | 1-8 | 1-1 | 5*02 | 100 |
| B-PLL13 | Yes | 3-23 | 3-9 | 4*02 | 100 |
ND, not detected.
In-frame productive IGH rearrangements are shown. The underlined IGHV genes are frequently used in MCL patients.41